tiprankstipranks

Markus Renschler Insider Profile

4 Followers
Markus Renschler, Sr. VP, Oncology Clinical Dev at Pharmacyclics, holds 1.39K shares in Pharmacyclics (Ticker: PCYC), holds 1.10M shares in Cyteir Therapeutics (Ticker: CYT). Most recently, Markus Renschler ― shares of Pharmacyclics on ― for an estimated value of ―.
tipranks
Markus Renschler

Markus Renschler
Pharmacyclics (PCYC)
Sr. VP, Oncology Clinical Dev

Not Ranked
Ranked #27,438 out of 99,024 Corporate Insiders
Markus Renschler has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

Markus Renschler does not currently own shares as a corporate insider.
A breakdown of Markus Renschler's holdings

Insider Roles

Markus Renschler does not currently hold a role as a corporate insider.
Roles that Markus Renschler holds in companies

Most Profitable Insider Trade

Stock:
Cyteir Therapeutics
(CYT)
Rating:Informative Buy
Date:Dec 23, 2022 - Dec 23, 2023
Return:+116.30%
The most profitable trade made by Markus Renschler

Markus Renschler's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
PCYC
Pharmacyclics
CYT
Cyteir Therapeutics
Mar 05, 2024
Informative Buy
35.00K
$3.32M
List of latest transactions for each holding click on a transaction to see Markus Renschler's performance on stock

Markus Renschler insider profile FAQ

What is the percentage of profitable transactions made by Markus Renschler?
The percentage of profitable transactions made by Markus Renschler is ―.
    What is the average return per transaction made by Markus Renschler?
    The average return per transaction made by Markus Renschler is ―.
      What stocks does Markus Renschler hold?
      Markus Renschler holds: PCYC, CYT stocks.
        What was Markus Renschler’s latest transaction?
        Markus Renschler latest transaction was an Uninformative Buy of ―.
          What was Markus Renschler's most profitable transaction?
          Markus Renschler’s most profitable transaction was an Informative Buy of CYT stock on December 23, 2022. The return on the trade was 116.30%.
            What is Markus Renschler's role in Pharmacyclics?
            Markus Renschler's role in Pharmacyclics is Sr. VP, Oncology Clinical Dev.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.